LLY - What Eli Lilly Is Getting With The Acquisition Of Morphic Holding
2024-07-09 09:38:59 ET
Summary
- Eli Lilly will acquire Morphic Holding for $3.2 billion, and the deal brings a phase 2b asset MORF-057 for the treatment of inflammatory bowel disease, and a preclinical pipeline.
- Eli Lilly to acquire Morphic Holding for $3.2 billion, bringing lead asset MORF-057 for IBD treatment.
- The acquisition provides Eli Lilly a shot on goal in the IBD market, despite potential risks associated with MORF-057 and pipeline.
Eli Lilly ( LLY ) announced that it will acquire Morphic Holding ( MORF ) for $57 per share, or $3.2 billion. The deal brings a lead asset MORF-057, an oral candidate targeting the ?4?7 receptor, for the treatment of inflammatory bowel diseases (‘IBD’) such as ulcerative colitis and Crohn’s disease. In my initiation article on Eli Lilly, I noted that the long-term upside does not depend solely on the company’s obesity pipeline and that I expect it to diversify its pipeline through business development, and this is what the Morphic deal represents....
What Eli Lilly Is Getting With The Acquisition Of Morphic Holding